Hygieia – a digital therapeutics company for insulin therapy – announced recently it is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.
Hygieia is known as the maker of d-Nav, the only FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient’s changing insulin needs, providing people who inject their insulin with a closed-loop system functionality.
Patients are able to get the correct insulin dose at each injection without the need for physician intervention. And studies have shown that nearly 90% of d-Nav patients have improved A1C levels within 90 days, without increasing the risk for hypoglycemia.
With the recent caps on insulin co-pays, there has been good progress in reducing the cost barrier for insulin therapy. And with d-Nav, dose is not a barrier either. Since the d-Nav Technology autonomously adjusts insulin dose recommendations at the time of injection, patients get the right dose without the need for weekly visits to a physician.
Hygieia is currently building the nation’s leading network of diabetes care centers driven by the d-Nav Technology. And Hygieia’s d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes is now in Michigan, Texas, Arizona, and North Carolina, with more states available soon. This program seamlessly fits into endocrinology practice operations to improve patient outcomes while providing an added revenue stream.
KEY QUOTES:
“This is a validation of our d-Nav Technology and its potential to expand the availability of closed-loop functionality for those who inject insulin, which is 90% of insulin users.”
“More than eight million Americans use insulin to treat their diabetes. This additional investment enables us to explore additional ways to bring d-Nav Technology to more insulin users, for safe, effective insulin therapy.”
- Eran Bashan, CEO and co-founder of Hygieia
